What gives with the IMProveMF combo study?
Posted: Tue Jun 02, 2026 3:42 pm
From the looks of the ASCO poster, Geron is having significant difficulty recruiting patients to take Imetelstat in combo with Ruxolitinib:
"The enrollment of the first patient in was on January 10, 2025. As of April 2026, Phase 1b
has 3 patients enrolled in Cohort A and 6 patients enrolled in Cohort B"
The total number of need patients is 15 and almost a year and a half later they have only recruited 9? These patients aren't being asked to come off of RUX, just add Imetelstat to it. In fact, they have discontinued Cohort A which required patients to have not received more than 24 weeks of RUX.
"The enrollment of the first patient in was on January 10, 2025. As of April 2026, Phase 1b
has 3 patients enrolled in Cohort A and 6 patients enrolled in Cohort B"
The total number of need patients is 15 and almost a year and a half later they have only recruited 9? These patients aren't being asked to come off of RUX, just add Imetelstat to it. In fact, they have discontinued Cohort A which required patients to have not received more than 24 weeks of RUX.